Mary Matyskiela is currently Executive Director of Molecular Sciences at a stealth-mode startup in the targeted protein degradation space. Mary received her B.S. in Chemistry from Yale University. She then went on to perform graduate work at the University of California San Francisco studying ubiquitin ligase mechanism, followed by postdoctoral studies at the University of California Berkeley on the architecture of the 26S proteasome. From there, she moved to Celgene/BMS where she spent 6 years developing targeted protein degradation technologies and expanding the horizons of molecular glue targeting through cereblon-CRL4.